US regulatory status: approved. Molecular target: Synaptosomal-associated protein 25.
- Target
- Synaptosomal-associated protein 25
- Mechanism
- Synaptosomal-associated protein 25 inhibitor
pharma · Lower limb spasticity · Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP)
Merz Therapeutics
Merz Pharmaceuticals GmbH
Merz Therapeutics drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
frankfurt am main, DE HQ
2020 Founded
1,312 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- frankfurt am main, DE
- Founded
- 2020
- Employees
- 1,312
- Programs
- 2
- Drugs
- 4
- Patents
- 0
Merz Therapeutics pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Merz Therapeutics drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Merz Therapeutics in public FDA and regional records.
-
Development asset linked to Merz Therapeutics in public FDA and regional records.
-
Development asset linked to Merz Therapeutics in public FDA and regional records.